ARAM Medical becomes Middle East supplier of Rockwell's Triferic renal anemia treatment

Rockwell Medical Inc., a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD), has signed an exclusive license and manufacturing supply agreement with Saudi-based ARAM Medical.

This agreement allows ARAM Medical to commercialize Rockwell’s Triferic and Calcitriol in the Middle East.

“We are excited to establish this strategic partnership with ARAM Medical to treat the large, growing ESRD population in the Middle East,” Robert Chioini, founder, chairman and CEO of Rockwell Medical, said. 

Chioini mentioned that the agreement validates the potential of Triferic to become a global standard in the health care industry for treating renal anemia.

“We continue to be focused on securing strategic partnerships that enable us to commercialize Triferic on a global scale,” Chioini said. “We believe Triferic is the only iron product that can effectively address the severe anemia dialysis patients worldwide suffer from. Working with our partner ARAM, we look forward to offering our life-changing therapy to this large ESRD population representing approximately 375,000 patients in the territory.”

Mahmoud al Naha, CEO of ARAM Medical, stated his company’s happiness and appreciation in securing the deal with Rockwell. He noted that the dialysis population in Saudi Arabia exceeds 25,000, and Triferic can become the method for improving these patients’ lives.

“ARAM Medical is a leading agent in the pharmaceutical field in Saudi Arabia and we have strong relationships throughout the territory,” al Naha said. “We value this new partnership with Rockwell U.S.A. As the exclusive agent in the Middle East, we will use our vast experience to ensure our efforts are successful in providing our patients with unique products to improve their quality of life.”